BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
    • Index insights
    • NME Digest
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Under threat: mRNA vaccine research
    • BioWorld at 35
    • Biopharma M&A scorecard
    • Bioworld 2025 review
    • BioWorld MedTech 2025 review
    • BioWorld Science 2025 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Coronavirus
    • More reports can be found here

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
BioWorld - Thursday, January 29, 2026
Home » Newsletters » BioWorld Science

BioWorld Science

April 30, 2002

View Archived Issues

Marketing application filed in E.U. for Axcan's photodynamic therapy

Read More

Chymase inhibition in the spotlight

Read More

The role of endothelin blockade in organ transplantation

Read More

Studies on immunosuppression with FK-778 a highlight at Transplant 2002

Read More

Cellegy withdraws Cellegesic NDA

Read More

Lexicon Genetics discovers new oncogene for development of anticancer drugs

Read More

FDA alerts to Actos and Avandia label modifications

Read More

Transplant 2002: IDEC-131 improves transplant graft survival in combination regimens

Read More

Chinese herbal medicine improves I/R injury to the kidney via activation of eNOS

Read More

Drug used for xerostomia may help prevent lung cancer

Read More

Combination of antimetabolite and thymidine phosphorylase inhibitor in clinical development at Taiho

Read More

New selective partial agonist at D4 receptors designed at German university

Read More

Dihydropyridine Y1 receptor antagonists reduce food intake in rat models

Read More

LY-402913, a selective MRP1 inhibitor with in vivo resistance-modulating activity

Read More

Orally active thrombin inhibitor advances to phase II clinical trials at Boehringer Ingelheim

Read More

Aventis and Fujisawa form alliance for marketing of Synercid

Read More

Genta and Aventis collaborate on Genasense development and commercialization

Read More

Hyseq collaborations mark first quarter

Read More

DiAthegen and TissueInformatics form obesity and type 2 diabetes joint venture

Read More

Antex Biologics presents pipeline development plans

Read More

Neotrofin fails to meet primary endpoint in Alzheimer's disease

Read More

Selective estrogens with preference for the ERalpha receptor claimed by Jenapharm

Read More

Pharmacor presents new anti-HIV agents

Read More

Enantiomerically pure antiarrhythmic compounds prepared at ARYx

Read More

New protein farnesyltransferase inhibitors described by Schering-Plough

Read More

Recent patent covers synthesis and use of new inhibitors of proinflammatory cytokine production

Read More

Novel Takeda compounds claimed for use in heart failure, etc.

Read More

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for Jan 28, 2025.
  • Today's news in brief

    BioWorld MedTech
    BioWorld MedTech briefs for Jan. 28, 2026.
  • DNA mutations or genetic disorder concept art

    Biallelic variants in COX18 identified as cause of Charcot-Marie-Tooth disease

    BioWorld Science

    Charcot-Marie-Tooth (CMT) disease is a group of clinically and genetically heterogeneous sensorimotor peripheral neuropathies. It is the most frequent inherited...

  • Brain with stroke illustration

    Brain-derived tau in blood predicts stroke severity and outcome

    BioWorld Science

    Brain-derived tau, a protein that is exclusive to the brain and detectable in the blood, could serve as an indicator of brain damage after an ischemic stroke. The...

  • Dice spelling out D-E-A-L-?, yes, no

    Muted and missing M&As: JPM deals absent in 2026

    BioWorld
    For years, the J.P. Morgan Healthcare Conference (JPM) kicked off with splashy headlines of major M&A activity among biopharma companies, but in 2026, the hype...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld MedTech
    • Today's news
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/Metabolic
    • Immune
    • Infection
    • Neurology/Psychiatric
    • NME Digest
    • Patents
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2026. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing